活细胞成像市场－全球产业规模、份额、趋势、机会及预测（按产品、应用、技术、最终用户、地区和竞争格局划分，2021-2031年）

全球活细胞成像市场预计将从 2025 年的 32.2 亿美元成长到 2031 年的 53.5 亿美元，复合年增长率为 8.83%。

这项技术透过延时显微镜技术，能够视觉化活体样本内部的细胞结构和动态过程，实现即时生物学分析。该市场的主要成长要素是慢性病发病率的上升以及由此带来的药物研发中对高内涵筛检的需求。根据美国癌症协会预测，到2024年，美国预计将新增约200万例癌症病例，因此需要对细胞研究和开发进行大量投资。

然而，市场扩张面临一个重大障碍：高解析度仪器需要大量的资本投入。这些高昂的成本阻碍了预算有限的小规模学术机构和生物技术公司采用这些仪器。此外，在显微镜载物台上维持生理条件以避免光毒性的技术复杂性也带来了操作上的挑战。这些困难使得长期实验难以进行，并阻碍了这些先进成像方法的广泛应用。

市场驱动因素

将人工智慧 (AI) 和机器学习技术整合到影像分析软体中，是推动市场发展的重要因素，从根本上改变了细胞​​数据的解读方式。这些计算工具能够自动完成细胞分割和追踪，使研究人员能够以最少的人工干预从海量图像数据集中提取有意义的动态数据。这项技术进步对于降低光毒性至关重要，而人工智慧增强的修復演算法能够减少影像撷取过程中的光照，从而在长期纵向研究中保持细胞活力。为了反映其在该领域的投入规模，诺和诺德基金会在2024年3月的「Gefion 推出」活动上承诺捐赠约6亿丹麦克朗，用于资助一台旨在加速细胞生物学和药物研发的新型人工智慧超级电脑。

同时，生命科学研究经费和私人投资的不断增长正推动先进显微镜系统在药物研发领域的应用。製药公司优先考虑高内涵筛检以识别治疗靶点，并需要强大的成像基础设施来支援即时动态分析。这笔资金的涌入支持了能够进行高通量处理的自动化活细胞平台的采购。根据罗氏公司于2024年3月发布的《2023年度报告》，该集团已投资132亿瑞士法郎用于研发，以加强其多元化的诊断和治疗产品组合。此外，公共部门的支持仍然是市场稳定的关键支柱。根据美国科学促进会（AAAS）于2024年3月发布的《2024年最终预算》更新报告，美国国立卫生研究院（NIH）共获得471亿美元的专案级资金，用于支持生物医学研究。

市场挑战

高解析度设备需要大量的资金投入，这是全球市场的一个主要阻碍因素。先进的活细胞影像系统前期成本高昂，设定了很高的进入门槛，尤其对于中小型生物技术公司和学术机构更是如此。这些机构通常预算有限，难以购买高性能显微镜平台。有限的资金迫使潜在买家推迟设备升级或继续使用过时的系统，这直接限制了製造商的销售量，并阻碍了其在成本敏感型细分市场的渗透。

科研基础设施经费削减进一步加剧了这种经济压力。根据美国科学促进会 (AAAS) 2024 年的一份报告，美国国立卫生研究院 (NIH) 的基本预算较上年度削减约 0.8%，这实际上降低了其购买科研设备的能力。这些联邦资金限制迫使科学研究机构优先考虑必要的营运支出，而非购买新的资本资产。因此，高昂的设备拥有成本，加上难以获得津贴，正在减缓成像技术的应用，并阻碍整体市场扩张。

市场趋势

随着研究人员越来越重视生理相关的微环境而非传统的二维培养，向三维类器官和球状体成像模型的转变正在改变整个产业。这种转变需要先进的显微镜解决方案，能够进行深层组织穿透和长期体积监测，精确捕捉厚生物基质内动态的细胞间相互作用。业界正在积极回应，开发专用的高通量系统来支援这些复杂的工作流程，尤其是在肿瘤学和再生医学领域。例如，赛多利斯公司在2024年2月发布的2023年度报告中显示，其销售额约为34亿欧元，这充分体现了市场对支持先进细胞培养应用解决方案的强劲需求。

多体学与活细胞数据的整合是重大飞跃，推动市场从形态学观察迈向全面的功能表型分析。透过将即时成像与空间转录组学和蛋白​​质组学相结合，科学家现在可以绘製驱动细胞行为的分子机製图谱。这项能力对于精准医疗和生物标记发现至关重要。这一趋势正在推动结合光学显微镜和空间分析技术的混合平台的收购。为了佐证这项策略多元化带来的财务影响，布鲁克公司在2024年2月发布的「2023年第四季及全年业绩报告」中报告称，全年销售额达29.6亿美元，这主要得益于产品系列扩张。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球活细胞成像市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（设备、耗材、软体、服务）
  • 依应用领域（细胞生物学、干细胞、发育生物学、药物发现）
  • 透过技术（延时显微镜、光漂白后萤光恢復、高内涵筛检、萤光共振能量转移等）
  • 依最终用户（製药/生技公司、学术/研究机构、合约研究组织）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美活细胞成像市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲活细胞成像市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区活细胞成像市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲活细胞成像市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲活细胞成像市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球活细胞影像市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bio-Rad Laboratories, Inc.
• Agilent Technologies Inc.
• Blue-Ray Biotech Corp.
• Axion BioSystems, Inc
• Curiosis Inc.
• Carl Zeiss AG
• Thermo Fisher Scientific Inc.
• Perkin Elmer Inc
• Danaher Corporation
• Nikon Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Live Cell Imaging Market is projected to expand from USD 3.22 Billion in 2025 to USD 5.35 Billion by 2031, reflecting a compound annual growth rate of 8.83%. This technology enables the visualization of internal cellular structures and dynamic processes within living specimens through time-lapse microscopy, thereby facilitating real-time biological analysis. The market is primarily driven by the increasing prevalence of chronic diseases and the consequent demand for high-content screening in pharmaceutical drug discovery. According to the American Cancer Society, approximately 2 million new cancer cases were expected to be diagnosed in the United States in 2024, necessitating substantial investment in cellular research and development.

However, market expansion encounters a major obstacle due to the significant capital investment needed for high-resolution instrumentation. These steep costs limit accessibility for smaller academic institutions and biotechnology firms operating with restricted budgets. Furthermore, the technical complexity of maintaining physiological conditions on a microscope stage to avoid phototoxicity presents an operational challenge; this difficulty complicates long-term experimentation and hinders the wider adoption of these advanced imaging modalities.

Market Driver

The incorporation of artificial intelligence and machine learning into image analysis software serves as a primary market accelerator, fundamentally altering how cellular data is interpreted. These computational tools automate the segmentation and tracking of cells, allowing researchers to derive meaningful kinetic data from extensive image datasets with minimal manual effort. This technological advancement is crucial for reducing phototoxicity, as AI-enhanced restoration algorithms permit lower light exposure during image acquisition, thereby preserving cell viability for prolonged longitudinal studies. Illustrating the scale of commitment to this field, the Novo Nordisk Foundation announced in its 'Launch of Gefion' in March 2024 a pledge of approximately DKK 600 million for a new AI supercomputer designed to expedite discoveries in cell biology and drug development.

Concurrently, the increase in life science research funding and private investments is driving the adoption of advanced microscopy systems for drug discovery. Pharmaceutical companies are placing greater priority on high-content screening to identify therapeutic targets, requiring robust imaging infrastructure that supports real-time kinetic analysis. This influx of capital supports the procurement of automated live cell platforms capable of high-throughput processing. According to Roche's 'Annual Report 2023' released in March 2024, the group invested CHF 13.2 billion in research and development to strengthen its diverse diagnostics and therapeutics portfolio. Moreover, public sector support remains a vital pillar for market stability; the American Association for the Advancement of Science reported in its 'FY 2024 Final Appropriations' update in March 2024 that the National Institutes of Health received a total program level budget of USD 47.1 billion to support biomedical research.

Market Challenge

The necessity for substantial capital investment to acquire high-resolution instrumentation acts as a primary restraint on the global market. Advanced live cell imaging systems involve significant upfront costs that create high barriers to entry, particularly for smaller biotechnology companies and academic institutions. These organizations frequently operate within fixed fiscal boundaries, making the procurement of premium microscopy platforms challenging. When capital resources are scarce, potential buyers are often compelled to delay equipment upgrades or continue using legacy systems, which directly limits sales volume for manufacturers and restricts market penetration in cost-sensitive segments.

This economic strain is further exacerbated by reductions in support for scientific infrastructure. As reported by the American Association for the Advancement of Science in 2024, the base budget for the National Institutes of Health faced a reduction of approximately 0.8 percent compared to the previous fiscal year, effectively diminishing the purchasing power for research instrumentation. Such constraints on federal funding necessitate that research facilities prioritize essential operational expenses over new capital assets. Consequently, the high cost of ownership combined with reduced grant availability slows the adoption rate of imaging technologies and impedes overall market expansion.

Market Trends

The shift toward 3D Organoid and Spheroid Imaging Models is transforming the sector, as researchers increasingly prioritize physiologically relevant microenvironments over traditional two-dimensional cultures. This transition necessitates advanced microscopy solutions capable of deep-tissue penetration and long-term volumetric monitoring to accurately capture dynamic cellular interactions within thick biological matrices. The industry is responding with dedicated high-throughput systems designed to support these complex workflows, particularly in oncology and regenerative medicine. Highlighting the scale of this operational expansion, Sartorius reported in its 'Annual Report 2023' in February 2024 that the company generated sales revenue of approximately EUR 3.4 billion, underscoring the strong market uptake for solutions enabling sophisticated cell culture applications.

The emergence of Multi-Omics Integration with Live Cell Data represents a significant leap forward, moving the market beyond morphological observation to comprehensive functional phenotyping. By correlating real-time imaging with spatial transcriptomics and proteomics, scientists can now map the molecular mechanisms driving cellular behavior, a capability that is critical for precision medicine and biomarker discovery. This trend is driving the acquisition of hybrid platforms that combine optical microscopy with spatial profiling technologies. Validating the financial impact of this strategic diversification, Bruker Corporation reported in its 'Fourth Quarter and Full Year 2023 Financial Results' release in February 2024 that full-year revenues reached USD 2.96 billion, driven by its expanding portfolio in spatial biology and cellular analysis.

Key Market Players

• Bio-Rad Laboratories, Inc.
• Agilent Technologies Inc.
• Blue-Ray Biotech Corp.
• Axion BioSystems, Inc
• Curiosis Inc.
• Carl Zeiss AG
• Thermo Fisher Scientific Inc.
• Perkin Elmer Inc
• Danaher Corporation
• Nikon Corporation

Report Scope

In this report, the Global Live Cell Imaging Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Live Cell Imaging Market, By Product

• Instruments
• Consumables
• Software
• Services

Live Cell Imaging Market, By Application

• Cell Biology
• Stem Cells
• Developmental Biology
• Drug Discovery

Live Cell Imaging Market, By Technology

• Time Lapse Microscopy
• Fluorescence Recovery After Photo Bleaching
• High Content Screening
• Fluorescence Resonance Energy Transfer
• Others

Live Cell Imaging Market, By End-Users

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations

Live Cell Imaging Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Live Cell Imaging Market.

Available Customizations:

Global Live Cell Imaging Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Live Cell Imaging Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Consumables, Software, Services)
  • 5.2.2. By Application (Cell Biology, Stem Cells, Developmental Biology, Drug Discovery)
  • 5.2.3. By Technology (Time Lapse Microscopy, Fluorescence Recovery After Photo Bleaching, High Content Screening, Fluorescence Resonance Energy Transfer, Others)
  • 5.2.4. By End-Users (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Live Cell Imaging Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Technology
  • 6.2.4. By End-Users
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Live Cell Imaging Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Technology
      • 6.3.1.2.4. By End-Users
  • 6.3.2. Canada Live Cell Imaging Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Technology
      • 6.3.2.2.4. By End-Users
  • 6.3.3. Mexico Live Cell Imaging Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Technology
      • 6.3.3.2.4. By End-Users

7. Europe Live Cell Imaging Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Technology
  • 7.2.4. By End-Users
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Live Cell Imaging Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Technology
      • 7.3.1.2.4. By End-Users
  • 7.3.2. France Live Cell Imaging Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Technology
      • 7.3.2.2.4. By End-Users
  • 7.3.3. United Kingdom Live Cell Imaging Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Technology
      • 7.3.3.2.4. By End-Users
  • 7.3.4. Italy Live Cell Imaging Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Technology
      • 7.3.4.2.4. By End-Users
  • 7.3.5. Spain Live Cell Imaging Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Technology
      • 7.3.5.2.4. By End-Users

8. Asia Pacific Live Cell Imaging Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Technology
  • 8.2.4. By End-Users
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Live Cell Imaging Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Technology
      • 8.3.1.2.4. By End-Users
  • 8.3.2. India Live Cell Imaging Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Technology
      • 8.3.2.2.4. By End-Users
  • 8.3.3. Japan Live Cell Imaging Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Technology
      • 8.3.3.2.4. By End-Users
  • 8.3.4. South Korea Live Cell Imaging Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Technology
      • 8.3.4.2.4. By End-Users
  • 8.3.5. Australia Live Cell Imaging Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Technology
      • 8.3.5.2.4. By End-Users

9. Middle East & Africa Live Cell Imaging Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Technology
  • 9.2.4. By End-Users
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Live Cell Imaging Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Technology
      • 9.3.1.2.4. By End-Users
  • 9.3.2. UAE Live Cell Imaging Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Technology
      • 9.3.2.2.4. By End-Users
  • 9.3.3. South Africa Live Cell Imaging Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Technology
      • 9.3.3.2.4. By End-Users

10. South America Live Cell Imaging Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Technology
  • 10.2.4. By End-Users
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Live Cell Imaging Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Technology
      • 10.3.1.2.4. By End-Users
  • 10.3.2. Colombia Live Cell Imaging Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Technology
      • 10.3.2.2.4. By End-Users
  • 10.3.3. Argentina Live Cell Imaging Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Technology
      • 10.3.3.2.4. By End-Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Live Cell Imaging Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bio-Rad Laboratories, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Agilent Technologies Inc.
• 15.3. Blue-Ray Biotech Corp.
• 15.4. Axion BioSystems, Inc
• 15.5. Curiosis Inc.
• 15.6. Carl Zeiss AG
• 15.7. Thermo Fisher Scientific Inc.
• 15.8. Perkin Elmer Inc
• 15.9. Danaher Corporation
• 15.10. Nikon Corporation

16. Strategic Recommendations

17. About Us & Disclaimer